SGLT2 inhibitors may cut risk for heart failure hospitalization
(HealthDay)—For patients with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), use of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1 ...
Sep 28, 2021
0
7